Study S001776

Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide

ClinicalTrials.gov record

Registration

Registration: NCT07225816
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 71
Start: 2025-11-07
Primary completion: 2026-12-13
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Liraglutide; DRUG:Oral Semaglutide; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1323-7355

Registered primary outcomes

Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40]
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161]
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No) [6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.